Ene Ette - Concepedia

Author

Ene Ette

Vertex Pharmaceuticals (United States)ORCID

Also Known As

Barry Dvorchik, Borje Darpo, Dion, Dion Brocks, E ETTE, E I Ette, E Van Ette, E. I. Ette, E.I. Ette, Ene Ette

161

Publications

Citations

H-Index

Concepts

All Affiliations

Vertex Pharmaceuticals (United States)Center for Drug Evaluation and Research University of Lagos Western Infirmary United States Food and Drug Administration

About

Ene Ette is an author at Vertex Pharmaceuticals (United States) specializing in medicine, pharmacology, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	1K
2	Engineering	2	2	77
3	Health Sciences	2	2	50
4	Public Health	1	1	14
5	Allergy	1	1	14

Ene Ette

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Stability and Performance of a Population Pharmacokinetic Model Ene Ette The Journal of Clinical Pharmacology Bootstrap Data ReplicatePharmacotherapyPhysiologically-based Pharmacokinetic ModelingPharmacodynamic ModelingPopulation Pharmacokinetic Model	1997	347
Population Pharmacokinetic Modeling: The Importance of Informative Graphics Ene Ette, Thomas M. Ludden Pharmaceutical Research	1995	176
Model Appropriateness and Population Pharmacokinetic Modeling Ene Ette, Paul J. Williams, Yong Ho Kim, The Journal of Clinical Pharmacology Pharmacokinetic ModelingPpk ModelMedicinePharmacoepidemiologyPatient Safety	2003	166
The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive Patricia Barditch‐Crovo, Carol Braun Trapnell, Ene Ette, Clinical Pharmacology & Therapeutics	1999	112
A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy Michael V. Seiden, Kenneth D. Swenerton, Ursula A. Matulonis, Gynecologic Oncology Mdr Inhibitor BiricodarMedicineMetronomic TherapyGynecologyPhase Ii Study	2002	98
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Deborah Toppmeyer, Andrew D. Seidman, Michaël Pollak, PubMed	2002	84
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Vivien Bramwell, Donald G. Morris, D. Scott Ernst, PubMed	2002	60
Analysis of animal pharmacokinetic data: Performance of the one point per animal design Ene Ette, Andrew W. Kelman, Catherine A. Howie, Journal of Pharmacokinetics and Biopharmaceutics Pharmacokinetic ModelingPhysiologically-based Pharmacokinetic ModelingMedicineAnimal DesignBiostatistics	1995	57
Estimating inestimable standard errors in population pharmacokinetic studies: The bootstrap with winsorization Ene Ette, Leonard C. Onyiah European Journal of Drug Metabolism and Pharmacokinetics Population Pharmacokinetic StudiesPharmacokinetic ModelingInestimable Standard ErrorsPharmacoepidemiologyBiostatistics	2002	42
Balanced Designs in Longitudinal Population Pharmacokinetic Studies Ene Ette, He Sun, Thomas M. Ludden The Journal of Clinical Pharmacology EngineeringPharmacokinetic ModelingPhysiologically-based Pharmacokinetic ModelingMedicineBiostatistics	1998	41

Page 1